Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

As reported by manilatimes.net

Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting ...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on manilatimes.net ↗

Market Samachar is a news aggregator. This article was originally published by manilatimes.net. Tap the button above to read the full story on their site.

INDIAN The US Federal Reserve's policy meeting due on Wednesday, September 16; how will it impact stocks, gold, and rupee? mint - markets
INDIAN Mint Explainer| What do Sebi’s proposed changes to closing auction mean for the markets? mint - markets
INDIAN Up 5,100% in one year! Breakwave Tanker Shipping ETF delivers highest returns on US-Iran war oil shock mint - markets
CRYPTO Bitcoin bucks tech selloff as AI safety concerns weigh on stocks CoinDesk: Bitcoin, Ethereum, Crypto News and Price Data
GLOBAL Oil prices up nearly 3% following new strikes on Saudi, Strait of Hormuz - Reuters Reuters
GLOBAL Heading off to uni? Here's what to insure against theft BBC News
GLOBAL Carney gambles on the world's biggest investors betting on Canada BBC News
GLOBAL Warsh and Trump on collision course International homepage

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

More from Market Samachar